Publication in the American Journal of Infection Control of a paper supporting the unprecedented microbial kill-rates of AsepticSure™ - an ozone vapor-based fumigant achieving ≥6 log₁₀ reductions for C. difficile, MRSA, VRE, E. coli and all other deadly bacterial pathogens tested - signals a promising new phase in the war against hospital and healthcare associated infections.
SAN FRANCISCO, CALIFORNIA – Medizone International, Inc. (OTCBB:MZEI) (OTCQB:MZEI) announced today that the highly efficacious properties of its newly-developed disinfection and decontamination technology, AsepticSure™, have received mainstream validation by way of publication in the prestigious American Journal of Infection Control.
